Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ocugen, Inc.HSGX · Entity 5550 | Director | April 16, 2018 | April 18, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ocugen, Inc.
Report date April 16, 2018 · Filed April 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2028-04-15 | Direct | 25,000 |
Reported balance
After 2018-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-16 · Grant · Acquired 25,000 · Balance 25,000 F1: Exercisable with respect to 8.33% of the shares in equal quarterly installments over 36 months of continuous service following the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 8.33% of the shares in equal quarterly installments over 36 months of continuous service following the vesting commencement date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
APPLIED GENETIC TECHNOLOGIES CORP
Report date November 30, 2022 · Filed December 01, 2022
Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Other · Disposed 143,021 · Balance 0 F1: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2023-09-18 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-30 · Disposition to issuer · Disposed 140,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.08 · Expires 2024-04-17 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-30 · Disposition to issuer · Disposed 99,156 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-07-31 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-30 · Disposition to issuer · Disposed 55,780 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2025-07-21 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-30 · Disposition to issuer · Disposed 80,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.57 · Expires 2026-07-07 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-30 · Disposition to issuer · Disposed 80,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2027-07-17 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-30 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2028-07-25 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-30 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2029-08-15 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-30 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2030-08-05 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-30 · Disposition to issuer · Disposed 169,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2031-07-27 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-11-30 · Disposition to issuer · Disposed 275,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2032-08-21 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-11-30 · Disposition to issuer · Disposed 442,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.
F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 442,000 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 12 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 442,000 shares Expires 2032-08-21 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 275,000 | Not disclosed Strike: $3.74 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 11 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 275,000 shares Expires 2031-07-27 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 169,000 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 10 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 169,000 shares Expires 2030-08-05 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 9 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2029-08-15 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $4.25 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 8 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-07-25 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $4.90 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 7 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2027-07-17 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $15.57 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 6 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2026-07-07 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $18.48 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 5 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2025-07-21 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,780 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 4 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,780 shares Expires 2024-07-31 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 99,156 | Not disclosed Strike: $14.08 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 3 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,156 shares Expires 2024-04-17 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 140,000 | Not disclosed Strike: $4.90 | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · derivative · entry 2 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires 2023-09-18 F2 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:14 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | OtherCommon Stock | 143,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023017 · form4.xml · nonDerivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. F1 · price: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. Read SEC document |
| August 21, 2022 Filed Aug 24, 2022 20:01 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 442,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001062993-22-018726 · form4.xml · derivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,000 Underlying: Common Stock · 442,000 shares Expires 2032-08-21 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:34 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Exercise / conversionStock Option (right to buy) · Derivative | 120,686 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001062993-22-005202 · form4.xml · derivative · entry 3 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,686 shares Expires 2023-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option is fully-vested and was exercisable for shares of common stock at any time until the expiration of the option at the holder's election. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:34 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | SaleCommon Stock | 9,950 | $2.18 | $21,691.00 |
DisclosureSEC source: 0001062993-22-005202 · form4.xml · nonDerivative · entry 2 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,021 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.15 to $2.22, inclusive. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:34 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Exercise / conversionCommon Stock | 120,686 | $0.35 | $42,240.10 |
DisclosureSEC source: 0001062993-22-005202 · form4.xml · nonDerivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:19 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Exercise / conversionStock Option (right to buy) · Derivative | 3,877 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001273636-21-000030 · edgar.xml · derivative · entry 2 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,877 shares Expires 2021-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option is fully-vested and was exercisable for shares of common stock at any time until the expiration of the option at the holder's election. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:19 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Exercise / conversionCommon Stock | 3,877 | $3.50 | $13,569.50 |
DisclosureSEC source: 0001273636-21-000030 · edgar.xml · nonDerivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 17:41 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001273636-21-000014 · edgar.xml · derivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-07-27 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 20:08 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 169,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-20-021805 · doc4.xml · derivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,000 Underlying: Common Stock · 169,000 shares Expires 2030-08-05 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 16:22 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Exercise / conversionStock Option (right to buy) · Derivative | 5,700 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001273636-19-000039 · edgar.xml · derivative · entry 2 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,841 Underlying: Common Stock · 5,700 shares Expires 2019-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option is fully-vested and was exercisable for shares of common stock at any time until the expiration of the option at the holder's election. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 16:22 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Exercise / conversionCommon Stock | 5,700 | $3.50 | $19,950.00 |
DisclosureSEC source: 0001273636-19-000039 · edgar.xml · nonDerivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 19:28 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000032 · edgar.xml · derivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-08-15 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 19:36 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | PurchaseCommon Stock | 2,380 | $3.34 | $7,949.20 |
DisclosureSEC source: 0001273636-18-000079 · edgar.xml · nonDerivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,708 Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 16:57 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001273636-18-000020 · edgar.xml · derivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-07-25 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 21:10 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0000899243-18-010326 · doc4.xml · derivative · entry 1 Washer Susan B. · CIK 0001598540 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-15 F1 · derivative.exercise_date: Exercisable with respect to 8.33% of the shares in equal quarterly installments over 36 months of continuous service following the vesting commencement date. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 20:37 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0000899243-17-018470 · doc4.xml · derivative · entry 1 Washer Susan B. · CIK 0001598540 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-07-17 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.